查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493202

美國核醫學市場規模、佔有率、趨勢分析報告：按產品、按應用、按最終用途、按國家、細分市場預測，2024-2030 年

U.S. Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostic (SPECT, PET), Therapeutic (Alpha, Beta Emitters, Brachytherapy)), By Application, By End-use, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

美國核子醫學市場成長與趨勢：

Grand View Research最新報告顯示，預計2030年美國核醫市場規模將達122.7億美元，2024年至2030年複合年成長率為12.6%。

這個市場主要是由癌症和心血管疾病盛行率不斷上升所推動的。根據 CDC 2023 年 5 月的估計，美國每年約有 805,000 人經歷心臟病發作，其中 605,000 人經歷首次心臟病發作。

因此，2018年至2019年，美國政府每年在心臟病預防和治療上的支出約為2,390億美元。這包括藥品和醫療服務的費用。某些因素，例如飲酒、飲食不當和缺乏鍛煉，可能導致癌症和心臟相關疾病。因此，美國癌症和心血管疾病的發生率正在迅速增加，對核子醫學的需求很可能會增加。癌症盛行率的整體上升將推動市場成長，因為接受治療的患者數量將會增加，早期診斷和治療的需求也會增加。

核子醫學技術進步是核子醫學市場的成長動力。Technetium-99m是放射性藥物領域應用最廣泛的放射性同位素之一。除Technetium-99m外，其他廣泛使用的放射性同位素包括碘131、銦111和氟18。這些醫用同位素在放射性藥理學中發揮重要作用，有助於實驗室中藥物分佈和遷移的研究。此外，FDA最近的核准預計將推動核醫學市場的進一步擴大。

2023年9月，美國FDA核准Cyclopharm開發的Technegas用於核醫灌注/通氣肺部掃描，以診斷肺動脈栓塞。使用 Techne 氣體技術的通氣閃爍閃爍圖術使用Technetium-99m (Tc-99m) 標記的碳奈米顆粒 (CNP)。在使用伽馬攝影機進行肺部成像之前，患者吸入藥物生成的奈米顆粒，這些奈米顆粒使用 Cyclopharm 子公司 Cyclomedica 製造的現場發生器霧化。

對準確診斷和治療方法的需求不斷成長正在推動核醫學市場的成長。目前可用的癌症治療方案，例如化療和放射線治療，涉及藥物和放射線的使用，但其準確性可能並不完美。此外，這些治療方法的主要缺點是影響全身或目標區域周圍的健康器官。放射性同位素優於這些技術，因為它們可以特異性靶向腫瘤而不影響周圍器官。因此，與這些診斷和治療方法相關的益處可能會推動這些領域對放射性藥物的需求。越來越多的組織採取舉措來滿足對核醫學日益成長的需求，預計將推動市場成長。例如，2023年8月，美國國家核安局（NNSA）計劃在未來20年內斥資數百億美元，對其核子研究和生產基礎設施進行現代化改造。據估計，這將擴大患者接受核醫手術的機會，並改善整體健康和福祉。

癌症和心血管疾病等慢性病的盛行率不斷上升，以及核子醫學作為治療這些疾病的現有治療技術的更好選擇，預計將對市場成長產生積極影響。根據美國生物技術資訊中心 (NCBI) 2023 年 3 月的數據，美國每年進行約 2,000 萬例核醫/影像手術。為了滿足不斷成長的需求，公司正在投資研發新的加速器技術、檢測器系統、放射化學、影像處理軟體以及用於診斷和治療各種疾病的自動化處理模組。

美國核醫市場報告亮點

  • 以產品來看，診斷產品佔最大銷售佔有率，2023年將達71.2%。這是由於存在大量患者基礎以及單光子發射電腦斷層掃描 (SPECT) 和正子發射斷層掃描 (PET) 等先進技術的可用性。
  • 從應用來看，腫瘤學領域在市場上佔據主導地位，預計在預測期內將保持其主導地位。這是由於癌症的高發生率和對放射性藥物診斷的偏好。 Iomab-B（AML 適應症）等放射治療藥物可能核准，加上符合條件的患者數量增加，預計將推動市場成長。
  • 從最終用途來看，醫院行業主導市場並佔據最大的銷售佔有率。預計該細分市場在預測期內將保持其主導地位。由於醫院和診所的增加，美國核子醫學市場正在擴大。由於診斷和治療疾病的住院患者數量不斷增加，核醫產品的需求量很大。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國核子醫學市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國核子醫學市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析
    • 管道分析
    • 治療次數分析

第4章美國核子醫學市場：產品估算與趨勢分析

  • 美國核子醫學市場：產品儀表板
  • 美國核子醫學市場：產品變異分析
  • 美國核子醫學市場（按產品、按收益）
  • 診斷產品
  • 治療產品

第5章美國核子醫學市場：產品估算與趨勢分析

  • 美國核子醫學市場：產品儀表板
  • 美國核子醫學市場：產品變化分析
  • 美國核子醫學市場（按產品、治療量）
  • 診斷程序
  • 神經病學
  • 腫瘤學
  • 甲狀腺
  • 神經病學
  • 腫瘤學
  • 甲狀腺
  • 淋巴瘤
  • 骨轉移
  • 內分泌腫瘤
  • 肺部掃描
  • 其他

第6章美國核子醫學市場：最終用途估計與趨勢分析

  • 美國核子醫學市場：最終用途儀表板
  • 美國核子醫學市場：最終用途變化分析
  • 美國核子醫學市場（依最終用途、按收益）
  • 醫院/診所
  • 診斷中心
  • 其他

第7章 競爭狀況

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Eckert &Ziegler
    • Curium
    • GE Healthcare
    • Jubilant Life Sciences Ltd.
    • Bracco Imaging SPA
    • Nordion（Canada）, Inc.
    • The Institute For Radioelements（IRE）
    • NTP Radioisotopes SOC Ltd.
    • EczacIbasI-Monrol
    • Lantheus Medical Imaging, Inc.
    • The Australian Nuclear Science and Technology Organization
    • Novartis（Advanced Accelerator Applications）
    • Siemens Healthineers AG
Product Code: GVR-4-68040-261-6

U.S. Nuclear Medicine Market Growth & Trends:

The U.S. nuclear medicine market size is anticipated to reach USD 12.27 billion by 2030, registering a CAGR of 12.6%, from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing incidence of cancer and cardiovascular diseases. Cardiovascular diseases are the leading cause of death for people of most ethnic and racial groups in the U.S. According to the CDC estimates in May 2023, Division for Heart Disease and Stroke Prevention, in the U.S., about 805,000 people witness heart attack annually, of these 605,000 people witness first episode of heart attack.

Therefore, the U.S. government spent around USD 239 billion every year from 2018 to 2019 on prevention and treatment of heart diseases. This includes the cost of medicines and health care services. Certain factors such as alcohol consumption, improper diet, and lack of exercise can cause cancer and heart-related diseases. Hence, the rapid increase in the incidence of cancer and cardiovascular disorders is likely to boost the demand for nuclear medicine in the U.S. The overall increase in the prevalence of cancer will likely boost the number of patients undergoing treatment, which increases the need for early diagnosis and treatment, thereby driving market growth.

Technological advancement in the nuclear medicine is a growth driver for the nuclear medicine market. Technetium-99m stands out as one of the most extensively utilized radioisotopes in the realm of radiopharmaceuticals. Alongside Technetium-99m, other widely employed radioisotopes include Iodine-131, Indium-111, and Fluorine-18. These medical isotopes play crucial roles in radiopharmacology, facilitating the study of drug distribution and movement within laboratory subjects. Furthermore, recent approvals by the FDA are anticipated to catalyze further expansion in the nuclear medicine market.

In September 2023, the U.S. FDA approved Technegas developed by Cyclopharm for use in nuclear medicine perfusion/ventilation lung scans to diagnose pulmonary embolism. Technetium-99m (Tc-99m)-labeled Carbon Nanoparticles (CNP) are used in ventilation scintigraphy using the technology Technegas. Before undergoing lung imaging with a gamma camera, patients inhale the agent-produced nanoparticles, which are then aerosolized using on-site generators manufactured by Cyclopharm's subsidiary Cyclomedica.

Rising demand for accurate diagnostic & treatment methods serves as a growth driver for the nuclear medicine market. Currently, available cancer treatment options, such as chemotherapy and radiation therapy, involve the use of drugs & radiation, which may not be completely accurate. Moreover, these therapies have a major disadvantage of affecting the whole body or the healthy organs surrounding the target site. Radioisotopes offer an advantage over these techniques as they can specifically target the tumor without affecting the surrounding body parts. Thus, benefits associated with these diagnostic and treatment procedures will likely boost the demand for radiopharmaceuticals in these fields. An increase in organizations undertaking initiatives to help address the growing need for nuclear medicine is anticipated to impel market growth. For instance, in August 2023, National Nuclear Security Administration (NNSA) was planning to spend tens of billions of dollars to modernize its nuclear-related research and production infrastructure over the next two decades in the U.S. This is expected to expand patient access to nuclear medicine procedures, which is estimated to improve their overall health and wellbeing.

Increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases, and emergence of nuclear medicine as a better option to existing treatment methodologies for treatment of these diseases is anticipated to have a positive impact on market growth. According to National Center for Biotechnology Information (NCBI) in March 2023, around 20 million nuclear medicine & imaging procedures are conducted every year in the U.S. This rising volume of these procedures is expected to open new avenues in the market during the forecast period. To meet the increasing demand, companies are investing in R&D of new accelerator technology, detector systems, radiochemistry, imaging software, and automated processing modules for diagnosis and treatment of various diseases.

U.S. Nuclear Medicine Market Report Highlights:

  • Based on product, diagnostic products held the largest revenue share of 71.2% in 2023 owing to presence of large patient base and availability of advanced technologies such as Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)
  • Based on application, the oncology segment dominated the market and is anticipated to maintain its dominance over the forecast period. This is attributed to the high prevalence of cancer and increased preference for radiopharmaceutical diagnosis. The probable approval of radiotherapeutic agents such as Iomab-B (indicated for AML), coupled with growing target patient population, is expected to drive market growth
  • Based on end-use, the hospitals segment dominated the market and accounted for the largest revenue share. The segment is expected to continue its dominance over the forecast period. The nuclear medicine market in the U.S. is expanding due to the rise in the number of hospitals and clinics. The demand for nuclear medicine products is high owing to rising inpatient visits for diagnosis and treatment of diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End-use
    • 1.2.4. Country scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. End-use
    • 2.2.4. Country outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Nuclear Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer and cardiovascular diseases
      • 3.2.1.2. Technological advancement in nuclear medicine
      • 3.2.1.3. Growing demand for accurate diagnostic & treatment methods
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations pertaining to production, storage, and usage nuclear medicines
      • 3.2.2.2. High cost associated with diagnostic and therapeutic procedures
  • 3.3. U.S. Nuclear Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
    • 3.3.5. Procedural Volume Analysis
      • 3.3.5.1. Diagnostic Procedures
      • 3.3.5.1.1. SPECT
      • 3.3.5.1.2. PET
      • 3.3.5.2. Therapeutic Procedure

Chapter 4. U.S. Nuclear Medicine Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Nuclear Medicine Market: Product Dashboard
  • 4.2. U.S. Nuclear Medicine Market: Product Movement Analysis
  • 4.3. U.S. Nuclear Medicine Market by Product, Revenue
  • 4.4. Diagnostic Products
    • 4.4.1. Diagnostic Products market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. SPECT
      • 4.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.1. TC-99m
      • 4.4.2.1.2. TL-201
      • 4.4.2.1.3. GA-67
      • 4.4.2.1.4. I-123
      • 4.4.2.1.5. Other SPECT Products
    • 4.4.3. PET
      • 4.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.1.1. F-18
      • 4.4.3.1.2. SR-82/RB-82
      • 4.4.3.1.3. Other PET products
  • 4.5. Therapeutic Products
    • 4.5.1. Therapeutic Products market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Alpha Emitters
      • 4.5.2.1. Alpha Emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.1.1. RA-223
      • 4.5.2.1.2. Others
    • 4.5.3. Beta Emitters
      • 4.5.3.1. Beta Emitters market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.3.1.1. I-131
      • 4.5.3.1.2. Y-90
      • 4.5.3.1.3. SM-153
      • 4.5.3.1.4. Re-186
      • 4.5.3.1.5. Lu-117
      • 4.5.3.1.6. Other Beta Emitters
    • 4.5.4. Brachytherapy
      • 4.5.4.1. Brachytherapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.4.1.1. Cesium-131
      • 4.5.4.1.2. Iodine-125
      • 4.5.4.1.3. Palladium-103
      • 4.5.4.1.4. Iridium-192
      • 4.5.4.1.5. Other Brachytherapy Products

Chapter 5. U.S. Nuclear Medicine Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Nuclear Medicine Market: Product Dashboard
  • 5.2. U.S. Nuclear Medicine Market: Product Movement Analysis
  • 5.3. U.S. Nuclear Medicine Market by Product (Procedural Volume)
  • 5.4. Diagnostic Procedures
    • 5.4.1. Diagnostic Procedures market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. SPECT
      • 5.4.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. PET
      • 5.4.3.1. PET market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Therapeutic Applications
      • 5.4.4.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Neurology
    • 5.5.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Thyroid
    • 5.7.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. SPECT
      • 5.7.2.1. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. Therapeutic Applications
      • 5.7.3.1. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Neurology
    • 5.8.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Oncology
    • 5.9.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. Thyroid
    • 5.10.1. Thyroid market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.10.1.1. SPECT
      • 5.10.1.2. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.10.1.3. Therapeutic Applications
      • 5.10.1.4. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.11. Lymphoma
    • 5.11.1. Lymphoma market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.12. Bone Metastasis
    • 5.12.1. Bone Metastasis market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.12.1.1. SPECT
      • 5.12.1.2. SPECT market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.12.1.3. Therapeutic Applications
      • 5.12.1.4. Therapeutic applications market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.13. Endocrine Tumor
    • 5.13.1. Endocrine Tumor market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.14. Pulmonary Scans
    • 5.14.1. Pulmonary Scans market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.15. Others
    • 5.15.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Nuclear Medicine Market: End-use Estimates & Trend Analysis

  • 6.1. U.S. Nuclear Medicine Market: End-use Dashboard
  • 6.2. U.S. Nuclear Medicine Market: End-use Movement Analysis
  • 6.3. U.S. Nuclear Medicine Market by End-use, Revenue
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Diagnostic Centers
    • 6.5.1. Diagnostic Centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.6.1.1.

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Eckert & Ziegler
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Curium
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. GE Healthcare
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Jubilant Life Sciences Ltd.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Bracco Imaging S.P.A
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Nordion (Canada), Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. The Institute For Radioelements (IRE)
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. NTP Radioisotopes SOC Ltd.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. EczacIbasI-Monrol
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Lantheus Medical Imaging, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. The Australian Nuclear Science and Technology Organization
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Novartis (Advanced Accelerator Applications)
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Siemens Healthineers AG
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Nuclear Medicine Market, 2018 - 2030 (USD Million)
  • Table 3 U.S. Nuclear Medicine Market, by Product, 2018 - 2030 (USD Million)
  • Table 4 U.S. Nuclear Medicine Market, by Product (Procedural Volume), 2018 - 2030 (Number of procedures)
  • Table 5 U.S. Nuclear Medicine Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 U.S. Nuclear Medicine Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD Modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Nuclear Medicine Market: market outlook
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 U.S. Nuclear Medicine Market driver impact
  • Fig. 13 U.S. Nuclear Medicine Market restraint impact
  • Fig. 14 U.S. Nuclear Medicine Market: Product movement analysis
  • Fig. 15 U.S. Nuclear Medicine Market: Product outlook and key takeaways
  • Fig. 16 Diagnostic Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 I-123 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Other SPECT Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 PET market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Therapeutic Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Alpha Emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Beta Emitters products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Lu-117 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Other Beta Emitters market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other Brachytherapy Products market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Diagnostic procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 45 SPECT procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 46 PET procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 47 Therapeutic procedures estimate and forecast, 2018 - 2030 (Number of procedures)
  • Fig. 48 U.S. Nuclear Medicine Market: Application movement analysis
  • Fig. 49 U.S. Nuclear Medicine Market: Application outlook and key takeaways
  • Fig. 50 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 PET market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Thyroid Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Bone Metastasis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Therapeutic Applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Endocrine Tumor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Pulmonary Scans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 U.S. Nuclear Medicine Market: End-use movement analysis
  • Fig. 67 U.S. Nuclear Medicine Market: End-use outlook and key takeaways
  • Fig. 68 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Diagnostic Centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. Nuclear Medicine Market: Country movement analysis
  • Fig. 72 U.S. Nuclear Medicine Market: Country outlook and key takeaways
  • Fig. 73 U.S. Nuclear Medicine Market share and leading players
  • Fig. 74 Market share of key market players- U.S. Nuclear Medicine Market